Results 121 to 130 of about 9,635 (207)

Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis. [PDF]

J Pers Med
Aalbers BL, Amatngalim GD, Aarts EM, Rodenburg LW, den Hertog-Oosterhoff LA, Heijerman HGM, Beekman JM.   +6 more
europepmc   +1 more source

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants. [PDF]

Eur Respir J
Drai C, van der Woude HJ, Lexmond AJ, van den Hoorn T, Mol PGM, Leacy FP, Przybyszewska A, Sepodes B, Castelnovo T.   +8 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Eur Respir J
Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA.   +13 more
europepmc   +1 more source

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. [PDF]

Cells
Lo Cicero S, Castelli G, Ceci A, Cerio AM, Blaconà G, Virgulti M, Allushi S, Sette G, Spadaro F, Amato F, Melotti P, Sorio C, Cimino G, Biffoni M, Lucarelli M, Eramo A.   +15 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

Highly Effective Modulator Therapy in Cystic Fibrosis: Addressing Unusual Variants in the Middle East. [PDF]

Pulm Med
Isse S, Wahla AS, Uzbeck MH, Zoumot Z, Abuzakouk M, Shafiq I.   +5 more
europepmc   +1 more source